Every material Form 8-K NU SKIN ENTERPRISES, INC. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nu Skin reported third-quarter 2026 revenue of $311.0 million, down 14.6% from $364.2 million a year earlier, and a GAAP net loss of $0.7 million, or $(0.02) per diluted share, compared with net income of $17.1 million, or $0.34 per share. Excluding certain charges, third-quarter EPS was $0.10, and the company projects 2026 GAAP EPS of $(5.08) to $(4.98) on revenue of $1.26 billion to $1.29 billion, with the GAAP loss reflecting a $167.5 million valuation allowance on deferred tax assets.
Q3 2026 revenue was $311.0 million, down 14.6%, with an approximately 1.1% foreign-currency impact; the company said revenue came in within its guidance range.
Q3 GAAP operating margin was 1.6%, or 3.7% excluding certain charges, compared with 5.9% a year earlier.
Nine-month 2026 net loss was $248.7 million, or $(5.13) per diluted share, versus net income of $145.7 million a year earlier.
Q4 2026 revenue is projected at $310 million to $340 million, with GAAP EPS of $0.05 to $0.15; the company expects sequential growth in the fourth quarter.
Effective August 17, 2026, Nu Skin said Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence. Chayce Clark, the company's Executive Vice President, Chief Operating Officer and Chief Legal Officer, will lead Mr. Keisel's organization during his absence. The filing does not state how long the leave will last, so shareholders have no stated return date for the sales leadership role.
Effective date of leave: August 17, 2026
Justin Keisel, EVP and President of Global Sales, began a medical leave of absence
Chayce Clark, EVP, COO and Chief Legal Officer, will lead Keisel's organization during the leave
Nu Skin reported second-quarter 2026 revenue of $320.1 million, down 17.1% from $386.1 million, and a GAAP net loss of $249.8 million, or $5.14 per share, driven by a $78.9 million impairment charge and a $167.5 million tax charge for a valuation allowance on deferred tax assets. Excluding these charges, adjusted EPS was $0.20 versus $0.43 a year earlier, and the company set 2026 revenue guidance of $1.28 billion to $1.35 billion and adjusted EPS of $0.70 to $0.90.
Q2 2026 revenue was $320.1 million, down 17.1%, including a $4.0 million foreign exchange impact
GAAP EPS was $(5.14) versus $0.43; EPS excluding impairment and non-cash tax charges was $0.20
Q3 2026 guidance: revenue of $310 million to $340 million and adjusted EPS of $0.10 to $0.20
Full-year 2026 guidance: revenue of $1.28 billion to $1.35 billion, down 14% to 9%, and adjusted EPS of $0.70 to $0.90
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NU SKIN ENTERPRISES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →